A retrospective study assessing the outcomes of daratumumab-containing regimens in the Canadian real-world setting among relapsed multiple myeloma patients
Latest Information Update: 12 Jul 2022
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Daratumumab (Primary) ; Lenalidomide (Primary) ; Pomalidomide (Primary) ; Corticosteroid
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 Jul 2022 Results (n=583) assessing the outcomes of dara-containing regimens in the Canadian real-world setting, published in the British Journal of Haematology.
- 08 Aug 2021 New trial record
- 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association